MedTrace Logo

Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With Hypertension

NCT06359873 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58427

Last updated 2024-04-11

No results posted yet for this study

Summary

Based on the data of inpatients with hypertension and a cross-sectional study with a large sample size, this study aims to find the early warning value of the left anteroposterior atrial diameter for the possible occurrence of atrial fibrillation in patients with hypertension, and compare the advantages and disadvantages of the above two methods for the early warning of the risk of atrial fibrillation in patients with hypertension, so as to achieve the purpose of early identification of high-risk groups that may develop atrial fibrillation.

Conditions

Interventions

DIAGNOSTIC_TEST

CHA2DS2-VASc score, C2HEST score, and left atrial diameter (LAD)

CHA2DS2-VASc Score: Congestive heart failure (HF) \[1 point\], hypertension \[1 point\], age ≥ 75 years \[2 points\], diabetes \[1 point\], prior stroke or transient ischemic attack \[2 points\], vascular disease \[1 point\], age 65-74 years \[1 point\], and female gender\[1 point\]. C2HEST Score: Coronary artery disease or chronic obstructive pulmonary disease \[1 point each, 2 total points\]; hypertension \[1 point\]; elderly \[2 points for age ≥ 75 years\]; systolic HF \[2 points\]; and thyroid disease \[1 point for hyperthyroidism\]\[10\]. LAD: The LAD values of the enrolled patients were extracted by keyword search based on the results of echocardiography in the database.

Sponsors & Collaborators

  • The Second Affiliated Hospital of Chongqing Medical University

    lead OTHER

Principal Investigators

  • Yuehui Yin, MD · The Second Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2022-09-30
Completion
2023-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06359873 on ClinicalTrials.gov